# Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Canonical URL: https://biopharmsignal.com/news/CADL/candel-therapeutics-announces-initiation-global-pivotal-phase-3
Ticker: CADL
Company: Candel Therapeutics
Source: Candel Therapeutics
Published: 2026-06-30 00:05 EST
Original Source URL: https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-initiation-global-pivotal-phase-3
## Summary

Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab versus standard-of-care docetaxel chemotherapy in patients with metastatic, non-squamous, non-small cell lung cancer (NSCLC) with progressive disease despite prior

## Article Body
Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab versus standard-of-care docetaxel chemotherapy in patients with metastatic, non-squamous, non-small cell lung cancer (NSCLC) with progressive disease despite prior
## Recent Company News
- 2026-07-01 08:05 EST — [Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/CADL/candel-therapeutics-announces-inducement-grants-under-nasdaq-4) — Source: Candel Therapeutics
- 2026-06-30 00:05 EST — [Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors](https://biopharmsignal.com/news/CADL/candel-therapeutics-announces-initiation-global-pivotal-phase-3) — Source: Candel Therapeutics
- 2026-06-25 13:46 EST — [Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer](https://biopharmsignal.com/news/CADL/candel-therapeutics-appoints-mark-sims-as-chief-commercial-officer) — Source: Candel Therapeutics
- 2026-06-25 13:46 EST — [Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer](https://biopharmsignal.com/news/CADL/candel-therapeutics-announces-publication-in-the-lancet-oncology-of-pivotal-phase-3-data-demonstrating-significant-improvement-in-disease-free-survival-with-aglatimagene-besadenovec-can-2409-in-localized-prostate-cancer) — Source: Candel Therapeutics
- 2026-06-25 13:46 EST — [Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting](https://biopharmsignal.com/news/CADL/candel-therapeutics-reports-extended-clinical-benefit-over-multiple-clinical-endpoints-in-patients-from-phase-3-trial-of-aglatimagene-besadenovec-can-2409-in-localized-prostate-cancer-under-prolonged-follow-up-at-aua-2026-annual-meeting) — Source: Candel Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)